‘Too Many Tests’: Expert Panel Questions Novartis Trial Protocol For Rare Kidney & Blood Disorder Drug

Novartis spokesperson told News18 that the company is in the process of reviewing the minutes of the meeting and post consultation with our global teams, it will take the necessary next steps.

Leave a Reply

Your email address will not be published. Required fields are marked *